Annovis Bio (ANVS) Other Non-Current Assets (2019 - 2026)
Annovis Bio (ANVS) posted Other Non-Current Assets of $7495.0 for Q1 2026, little changed sequentially from $7495.0 in Q4 2025, and little changed YoY from $7495.0 in Q1 2025.
Annovis Bio (ANVS) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Annovis Bio has reported Other Non-Current Assets for 8 years, with the latest figure at $7495.0 in Q1 2026.
- Quarterly Other Non-Current Assets changed 0.0% year-over-year to $7495.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7495.0 (changed 0.0% YoY) and the FY2025 annual result came in at $7495.0, changed 0.0% from the prior year.
- Other Non-Current Assets was little changed at $7495.0 in Q1 2026 per ANVS's latest filing, from $7495.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $26022.0 in Q2 2023 and troughed at $5796.0 in Q1 2024.
- A 5-year average of $10999.4 and a median of $7495.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets soared 151.35% in 2023, then slumped 71.2% in 2024.
- Over 5 years, Other Non-Current Assets stood at $11238.0 in 2022, then surged by 85.05% to $20796.0 in 2023, then plunged by 63.96% to $7495.0 in 2024, then changed by 0.0% to $7495.0 in 2025, then changed by 0.0% to $7495.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $7495.0, $7495.0, and $7495.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 104.44 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 62.96 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 202.31 Mn |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - | 7,495.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,495.00 |
| Dec 31, 2025 | 7,495.00 |
| Sep 30, 2025 | 7,495.00 |
| Jun 30, 2025 | 7,495.00 |
| Mar 31, 2025 | 7,495.00 |
| Dec 31, 2024 | 7,495.00 |
| Sep 30, 2024 | 7,495.00 |
| Jun 30, 2024 | 7,495.00 |
| Mar 31, 2024 | 5,796.00 |
| Dec 31, 2023 | 20,796.00 |
| Sep 30, 2023 | 20,619.00 |
| Jun 30, 2023 | 26,022.00 |
| Mar 31, 2023 | 11,238.00 |
| Dec 31, 2022 | 11,238.00 |
| Sep 30, 2022 | 11,103.00 |
| Jun 30, 2022 | 10,353.00 |
| Mar 31, 2022 | 9,865.00 |
| Dec 31, 2021 | 9,865.00 |
| Sep 30, 2021 | 9,865.00 |
| Jun 30, 2021 | 9,865.00 |